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Background: Evidence that any delay in providing information
results in lack of treatment or admission, which might result in
death or irreversible harm to an individual, constitutes an emer-
gency. Involving youth in the process could help avoid an unnec-
essary lack of information, and might contribute to the
sustainable legacy of fighting cancer. Youth-development pro-
grammes and initiatives associated with awareness, education,
and eradication of cancer could decrease unnecessary deaths
caused by cancer. Ongoing youth-development projects and part-
nership campaigns could improve health awareness.
Methods: Analysis of 500 young people involved in a Rural
Youth Health-Development programme (RYHD) conducted by
Umvithi Youth Development and Department of Health in KwaZ-
ulu, Natal, showed an improved ability to care, teach, and prevent
cancer. Through the RYHD, 2500 community members underwent
training and tests to recognise symptoms, and others were diag-
nosed with cancer and related diseases that they were not aware
of.
Findings: As a result of the RYHD, many individuals took
positive action and full responsibility to decrease cancer risk,
such as quitting smoking, eating healthy food, and exercising
regularly.
Interpretation: Utilising youth for information distribution and
involvement in the fight against cancer could propel communities
towards sustainable improvement in health, and enhances
the ability of individuals to take responsibility for their own
health. Young people are founders and initiators of projects,
groups, and organisations; they are lobbyists, decision-makers,
and are a key element for building a successful and growing
community.
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Background: Many lung-cancer studies have shown that female
patients without a history of smoking and of Asian origin have a
good response to tyrosine-kinase inhibitors (TKIs). Epidermal
growth-factor receptor (EGFR) mutations are prevalent in these
patients, which explains the promising response to TKIs. How-
ever, prevalence of mutations in the EGFR gene and response to
TKIs in Indonesian patients with lung cancer has not been stud-
ied. We have begun preliminary work to collect cytological sam-
ples from 14 patients, to assess the prevalence of EGFR
mutations and related clinicopathological parameters such as
sex, age, stage, and response to TKIs.
Methods: Cytological slides were examined by pathologists
and tumour cells were microdissected, to isolate total DNA,
and sent to a certified reference laboratory in Jakarta. Direct
DNA sequencing was done against exon 19 and 21 of the EGFR
gene, which are the most frequent sites of mutation according
to literature.
Findings: EGFR mutations were found in 50% of patients
(n = 14); female patients had a higher frequency than male
patients (71% [5 of 7] vs. 29% [2 of 7]). Deletion of exon 19 was
more common than substitution mutations in exon 21, which
contributed up to 71% and 29% to the overall mutation rate,
respectively. EGFR mutation was not associated with age or other
clinicopathological parameters. Response to TKIs in patients with
and without EGFR mutations is currently being investigated.
Interpretation: EGFR mutations are more prevalent in Indone-
sian women than in men, and deletion of exon 19 being the most
common mutation type. The preliminary response of patients to
TKIs is being evaluated. Large prospective studies are needed to
evaluate the response to TKIs among Indonesians with EGFR
mutations.
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Background: Bladder cancer is among the five most common
malignancies worldwide, and recurrence of non-invasive
tumours makes it one of the most prevalent cancers. Cystoscopy
in conjunction with urine cytology is the gold standard for detec-
tion of bladder cancer; however, cystoscopy is invasive and
expensive, with low accuracy for high-grade disease. Urine cytol-
ogy has low sensitivity for detection of low-grade bladder cancer.
The aim of study was to quantitate cytokeratin 20 (CK20) mRNA
expression in exfoliated cells of urine in patients with transi-
tional-cell carcinoma (TCC), by use of SYBR Green real-time
PCR, which may be used as a non-invasive tool for follow-up of
patients with bladder cancer.
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